Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | PPIA | P62937 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4647333 | 0.86 | PTPN1 (0.53) | PTPN1MGLLLRRK2F10PPIA | |
| SCHEMBL3220243 | 0.82 | PTPN1 (0.54) | PTPN1HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL4646366 | 0.80 | PTPN1 (0.61) | PTPN1MRGPRX4 | |
| SCHEMBL4646708 | 0.80 | PTPN1 (0.60) | PTPN1ENPP2MRGPRX4 | |
| SCHEMBL4643501 | 0.79 | PTPN1 (0.62) | PTPN1MRGPRX4 | |
| SCHEMBL4646595 | 0.77 | PTPN1 (0.53) | PTPN1LRRK2MRGPRX4 | |
| SCHEMBL4648546 | 0.76 | PTPN1 (0.57) | PTPN1 | |
| SCHEMBL4646706 | 0.76 | PTPN1 (0.57) | PTPN1MGLLMRGPRX4 | |
| SCHEMBL4646906 | 0.76 | PTPN1 (0.53) | PTPN1 | |
| SCHEMBL3920457 | 0.76 | PTPN1 (0.61) | PTPN1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | PTPN1 10/4885MGLL 730/4885LRRK2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.